Full results from the phase III OLYMPIA 1 trial evaluating the efficacy and safety of nemolizumab in adults with moderate-to-severe prurigo nodularis have been published in JAMA Dermatology, showing the trial met all primary and key secondary endpoints1
Data were consistent with OLYMPIA 2 trial results, reinforcing the potential of nemolizumab monotherapy to demonstrate rapid and sustained improvements in core signs and symptoms of prurigo nodularis: skin lesions, itch and sleep disturbance – at Week 16 and Week 241,2
In the OLYMPIA 1 trial, a significantly higher proportion of nemolizumab-treated patients achieved an itch-free or nearly itch-free state as early as Week 4 compared to those receiving placebo1
Nemolizumab is a first-in-class monoclonal antibody that specifically targets IL-31 receptor alpha, inhibiting the signaling of IL-31. IL-31 is a neuroimmune cytokine that is known to drive key signs and symptoms of prurigo nodularis3,4

ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SWX:GALD) today announced that full results from the phase III OLYMPIA 1 trial, a 24-week study which evaluated the efficacy and safety of nemolizumab monotherapy in adults with moderate-to-severe prurigo nodularis, were published in JAMA Dermatology.1 The trial met both primary and all key secondary endpoints, showing that nemolizumab-treated patients had significantly higher improvements in itch and skin lesions when compared to those receiving placebo at Week 16, with a rapid and clinically meaningful response on itch and sleep disturbance observed as early as Week 4.1 Nemolizumab was well-tolerated, and its safety profile was generally consistent with previous studies.1